US4897264A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Human gamma interferon-specific receptor protein, antibody against said protein, methods for obtaining said protein and said antibody and compositions containing said protein and antibody
Assignee: Yeda Research and Development Co Ltd
•
Filing: 1987-03-27
•
Granted: 1990-01-30
•
Expires: 2007-03-27
Abstract
Abstract Analysis of [ 125 I]. interferon gamma cross-linked to its receptor on various human cells by SDS-PAGE revealed that there are at least three different types of human interferon gamma receptors. In WISH, HeLa, FS11 and the other tissue cells an Mr 90,000-105,000 receptor was found. In monocytes and in the myeloid cell line KG-1 an Mr 140,000 receptor was found while in Daudi lymphoblastoid cells an Mr 95,000-115,000 receptor was found. The various receptors were isolated from these cells by extraction followed by affinity chromotography on an immobilized interferon gamma column. The resulting purified preparations retained their original affinity for interferon gamma and were used for immunizing mice and subsequent development of highly specific antibodies.
Inventors
- 👤 Daniela Novick
- 👤 Patricia Orchansky
- 👤 Dina Fischer
- 👤 Menachem Rubinstein
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:35
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2866; A; A61; A61K; A61K39/00; A61K39/395; A61P; A61P43/00; C07K14/00; C07K14/435; C07K14/705; C07K14/715; A61K38/00
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
21 words
A human gamma inteferon-specific receptor protein in a soluble and at least partially purified form, said protein not being an immunoglobulin.
Claim 2
Dependent Claim
21 words
A human gamma inteferon-specific receptor protein in a soluble and at least partially purified form, said protein not being an immunoglobulin.
Claim 3
Dependent Claim
25 words
The receptor protein of claim 1, which is a receptor protein of WISH, Hela and FS-11 cells having an approximate molecular weight of 90,000-105,000 dalton.
Claim 4
Dependent Claim
24 words
The receptor protein of claim 1, which is a receptor protein of monocytes and KG-1 cells having an approximate molecular weight of 140,000 dalton.
Claim 5
Dependent Claim
23 words
The receptor protein of claim 1, which is a receptor protein of Daudi lymphoblastoid cells having an approximate molecular weight of 95,000-115,000 dalton.
Claim 6
Dependent Claim
8 words
An antibody against the protein of claim 1.
Claim 7
Dependent Claim
8 words
An antibody against the protein of claim 2.
Claim 8
Dependent Claim
8 words
An antibody against the protein of claim 3.
Claim 9
Dependent Claim
8 words
An antibody against the protein of claim 4.
Claim 10
Dependent Claim
11 words
A composition comprising interferon gamma and the antibody of claim 1.
Claim 11
Dependent Claim
30 words
The composition of claim 9 comprising antibodies against at least one of the human interferon gamma receptors, but lacking an antibody against at least one other human interferon gamma receptor.
Claim 12
Dependent Claim
15 words
The composition of claim 10, lacking an antibody against the receptor protein of claim 2.
Claim 13
Dependent Claim
15 words
The composition of claim 10, lacking an antibody against the receptor protein of claim 3.
Claim 14
Dependent Claim
15 words
The composition of claim 10, lacking an antibody against the receptor protein of claim 4.
Claim 15
Dependent Claim
27 words
A composition comprising antibodies against at least one of the human interferon gamma receptors, but lacking an antibody against at least one other human interferon gamma receptors.
Claim 16
Dependent Claim
27 words
A composition comprising antibodies against at least one of the human interferon gamma receptors, but lacking an antibody against at least one other human interferon gamma receptors.
Claim 17
Dependent Claim
21 words
A composition comprising human interferon gamma and soluble receptor of claim 1 for controlling the therapeutical effect of human interferon gamma.
Claim 18
Dependent Claim
21 words
The composition comprising human interferon gamma and soluble receptor of claim 2 for controlling the therapeutical effect of human interferon gamma.
Claim 19
Dependent Claim
21 words
The composition comprising human interferon gamma and soluble receptor of claim 3 for controlling the therapeutical effect of human interferon gamma.
Claim 20
Dependent Claim
21 words
The composition comprising human interferon gamma and soluble receptor of claim 4 for controlling the therapeutical effect of human interferon gamma.
Claim 21
Dependent Claim
10 words
A human interferon gamma-specific receptor protein in substantially pure form.
Claim 22
Dependent Claim
10 words
A human interferon gamma-specific receptor protein in substantially pure form.
Claim 23
Dependent Claim
26 words
The receptor protein of claim 19, further characterized as a receptor protein of WISH, Hela and FS-11 cells having an approximate molecular weight of 90,000-115,000 daltons.
Claim 24
Dependent Claim
25 words
The receptor protein of claim 19, further characterized as a receptor protein of monocytes and KG-1 cells having an approximate molecular weight of 140,000 daltons.
Claim 25
Dependent Claim
24 words
The receptor protein of claim 19, further characterized as a receptor protein of Daudi lymphoblastoid cells having an approximate molecular weight of 95,000-115,000 daltons.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-01-29 | 1993-07-31 | 1994-01-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-01-29 | 1997-07-31 | 1998-01-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-01-29 | 2001-07-31 | 2002-01-30 | $7700.00 | Window Closed / Lapsed |